July 31, 2025 argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
July 24, 2025 argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
June 20, 2025 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
Follow us
Get the latest news and info via our social media channels.